C07K

Follow

Stats

Description

PEPTIDES (peptides containing -lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00)

Subclasses

Not Available
Subclass Title
1/00 General processes for the preparation of peptides
1/02 General processes for the preparation of peptides in solution
1/04 General processes for the preparation of peptides on carriers
1/06 General processes for the preparation of peptides using protecting groups or activating agents
1/08 General processes for the preparation of peptides using protecting groups or activating agents using activating agents

more results

Recent Patents

Not Available
Patent #TitleFiling DateIssue DatePatent Owner
9572820 Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits May 10, 12 Feb 21, 17 , STC.UNM
9572829 Treatment of ocular disorders Mar 20, 15 Feb 21, 17 , MASSACHUSETTS EYE & EAR INFIRMARY
9572835 Induced activation in dendritic cells Mar 10, 15 Feb 21, 17 , BAYLOR COLLEGE OF MEDICINE
9572837 Reducing immune tolerance induced by PD-L1 Apr 07, 16 Feb 21, 17 , INNOVATIVE CELLULAR THERAPEUTICS CO., LTD.
9572861 Engineered polypeptide agents for targeted broad spectrum influenza neutralization Apr 08, 16 Feb 21, 17 , MASSACHUSETTS INSTITUTE OF TECHNOLOGY
9572862 Methods for promoting lipolysis and oxidation in liver and adipose tissue using catestatin Apr 01, 13 Feb 21, 17 , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
9572866 Urocortin 2 analogs and uses thereof Jul 17, 15 Feb 21, 17 , RESEARCH DEVELOPMENT FOUNDATION
9572867 Treatment of short bowel syndrome patients with colon-in-continuity Oct 05, 16 Feb 21, 17 , SHIRE-NPS PHARMACEUTICALS, INC.
9572869 Chimeric fibronectin matrix mimetics and uses thereof Jun 18, 15 Feb 21, 17 , UNIVERSITY OF ROCHESTER
9572870 Delivery of therapeutic compounds to the brain and other tissues Feb 05, 15 Feb 21, 17 , BIOMARIN PHARMACEUTICAL INC.
9572873 Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins Jul 07, 15 Feb 21, 17 , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
9572879 ROBO2 inhibitory compositions comprising SLIT2-binding extracellular domain of ROBO2 Jan 04, 13 Feb 21, 17 , BOSTON MEDICAL CENTER CORPORATION
9572896 In vivo production of proteins Aug 12, 15 Feb 21, 17 , MODERNATX, INC.
9572897 Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins Feb 12, 16 Feb 21, 17 , MODERNATX, INC.
9572898 Functionalized fluorine containing phthalocyanine molecules Sep 09, 14 Feb 21, 17 , SETON HALL UNIVERSITY
9572899 Compositions for enhancing transport of molecules into cells Nov 05, 08 Feb 21, 17 , AVI BIOPHARMA INC.
9572900 Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate Sep 17, 13 Feb 21, 17 , GEMVAX & KAEL CO., LTD.
9573973 Separation method and separation matrix Apr 22, 13 Feb 21, 17 , GE HEALTHCARE BIOPROCESS R&D AB
9573974 Multi-leu peptides and analogues thereof as selective PACE4 inhibitors and effective antiproliferative agents Jan 08, 14 Feb 21, 17 , LA SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA-SCIENCES SANTE ET HUMAINES S.E.C.
9573975 Melanoma antigen peptide and uses thereof May 22, 12 Feb 21, 17 , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE NANTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE D'ANGERS;

more results

Recent Publications

Not Available
Publication #TitleFiling DatePub DatePatent Owner
2017/0042,130 Rodents with Conditional Acvr1 Mutant Alleles Oct 27, 16 Feb 16, 17 , Not available
2017/0042,967 TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS Mar 09, 16 Feb 16, 17 , Not available
2017/0042,972 USE OF CTLA4 COMPOUND FOR ACHIEVING DRUG-FREE REMISSION IN SUBJECTS WITH EARLY RA Apr 23, 15 Feb 16, 17 , Not available
2017/0042,980 Degradation of Beta-Amyloid Proteins With Keratinase Oct 31, 16 Feb 16, 17 , Not available
2017/0042,986 METHODS OF TREATMENT USING ALPHA-1-ANTITRYPSIN COMPOSITIONS Mar 18, 16 Feb 16, 17 , Not available
2017/0042,988 ANTIGENS OF PNEUMOCYSTIS MURINA AND USES THEREOF May 04, 15 Feb 16, 17 , Not available
2017/0042,991 COMPOSITIONS COMPRISING GLUTEN PEPTIDES AND USES THEREOF Apr 24, 15 Feb 16, 17 IMMUSANT, INC.,
2017/0042,995 Combination Vaccine Devices and Methods of Killing Cancer Cells Apr 30, 15 Feb 16, 17 ,
2017/0042,996 RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF PRODUCING THE SAME Apr 14, 15 Feb 16, 17 ,
2017/0042,997 VACCINE Apr 29, 15 Feb 16, 17 MEDIZINISCHE HOSCHSCHULE HANNOVER,
2017/0043,003 NEW M.TUBERCULOSIS VACCINES Apr 09, 15 Feb 16, 17 ,
2017/0043,008 RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE Oct 14, 16 Feb 16, 17 BAVARIAN NORDIC A/S,
2017/0043,011 SYNTHETIC HEPATITIS C GENOME AND METHODS OF MAKING AND USE Oct 27, 16 Feb 16, 17 ,
2017/0043,014 TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 May 05, 15 Feb 16, 17 NOVO NORDISK A/S,
2017/0043,020 ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA Jul 14, 16 Feb 16, 17 ,
2017/0043,031 IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER Apr 27, 15 Feb 16, 17 PIERRE FABRE MEDICAMENT,
2017/0043,033 ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING Apr 21, 15 Feb 16, 17 RINAT NEUROSCIENCE CORP.,
2017/0043,034 METHODS OF USING ANTI-STEAP1 ANTIBODIES AND IMMUNOCONJUGATES Jan 23, 15 Feb 16, 17 GENENTECH, INC.,
2017/0043,035 METHODS AND COMPOSITIONS FOR TREATING METASTATIC BREAST CANCER AND OTHER CANCERS IN THE BRAIN Apr 24, 15 Feb 16, 17 ,
2017/0043,039 METHOD FOR MEASURING TOXICITY OF HUMAN CSF Apr 16, 15 Feb 16, 17 KYOWA HAKKO KIRIN CO., LTD.,

more results

Patents Issued To Date - By Filing Year

Average Time to Issuance

We are sorry but your current selection exceeds the maximum number of follows () for this membership level. Upgrade to our Level for up to follows!

UPGRADE MEMBERSHIP CANCEL
We are sorry but Dashboard Viewer is not able to follow the Technologies/Sub-Technologies.